🕵️ Lantern Pharma Inc. ($LTRN)
SEC insider & ownership activity, last 12 months · CIK 1763950 · every row links its SEC filing
Over the last 12 months insiders bought $200K with no open-market selling against it. Keyser D Jeffrey bought $100K in discretionary trades (May). No red-flag 8-Ks in the window.
Monthly net open-market insider flow, last 12 months (up = net buying)
Insider flow
2 buyers, $200K (2 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Keyser D Jeffrey | 1 | $100K | 0 | – | May 12, 2026 |
| Schalop Lee Troy | 1 | $100K | 0 | – | May 12, 2026 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Thomas A. Satterfield, JR. | 7.6% | 13G | Jul 23, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Jun 1, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 1, 2026 | filing ↗ |
| Earnings (2.02) | May 15, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 15, 2026 | filing ↗ |
| Material agreement (1.01) | May 12, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | May 12, 2026 | filing ↗ |
| Other events (8.01) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 9, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 9, 2026 | filing ↗ |
| Earnings (2.02) | Mar 30, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Mar 30, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 30, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jan 22, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jan 22, 2026 | filing ↗ |
| Earnings (2.02) | Nov 13, 2025 | filing ↗ |
| Reg FD disclosure (7.01) | Nov 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 13, 2025 | filing ↗ |
| Shareholder vote (5.07) | Sep 19, 2025 | filing ↗ |
| Earnings (2.02) | Aug 13, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 13, 2025 | filing ↗ |